Stoke Therapeutics (NASDAQ:STOK) shares rose 8.8% on Tuesday following a better than expected earnings announcement. The stock traded as high as $22.38 and last traded at $21.35, approximately 246,200 shares changed hands during trading. An increase of 12% from the average daily volume of 219,618 shares. The stock had previously closed at $19.62.

The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.21.

STOK has been the topic of several recent research reports. BidaskClub raised shares of Stoke Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 1st. Cowen reissued a “buy” rating on shares of Stoke Therapeutics in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Stoke Therapeutics in a research report on Monday, December 9th. Wedbush assumed coverage on shares of Stoke Therapeutics in a research report on Tuesday, December 17th. They set an “outperform” rating and a $31.00 price target for the company. Finally, Zacks Investment Research cut shares of Stoke Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $34.57.

In other Stoke Therapeutics news, COO Huw M. Nash sold 49,143 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $25.89, for a total transaction of $1,272,312.27. Following the completion of the sale, the chief operating officer now owns 6,324 shares of the company’s stock, valued at approximately $163,728.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Apple Tree Partners IV L.P. purchased a new stake in shares of Stoke Therapeutics in the 4th quarter worth about $475,340,000. Gilder Gagnon Howe & Co. LLC lifted its position in shares of Stoke Therapeutics by 0.8% in the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,876,191 shares of the company’s stock worth $40,319,000 after purchasing an additional 14,568 shares during the period. FMR LLC lifted its position in shares of Stoke Therapeutics by 25.1% in the 4th quarter. FMR LLC now owns 554,397 shares of the company’s stock worth $15,701,000 after purchasing an additional 111,384 shares during the period. Victory Capital Management Inc. lifted its position in shares of Stoke Therapeutics by 5,209.8% in the 4th quarter. Victory Capital Management Inc. now owns 207,774 shares of the company’s stock worth $5,809,000 after purchasing an additional 203,861 shares during the period. Finally, State Street Corp lifted its position in shares of Stoke Therapeutics by 22.1% in the 4th quarter. State Street Corp now owns 169,744 shares of the company’s stock worth $4,807,000 after purchasing an additional 30,765 shares during the period.

The company’s 50-day moving average price is $24.99 and its 200 day moving average price is $25.20. The stock has a market capitalization of $642.16 million and a PE ratio of -11.25.

About Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Featured Article: Marijuana Stocks

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.